Skip Nav Destination
Issues
1 February 2023
-
Cover Image
Cover Image
STRO-002 is a homogeneous anti-FolRα ADC. The structure of STRO-002, which consists of a high affinity anti-FolRα antibody (SP8166) conjugated to a novel cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239). Read the full article by Li and colleagues on page 155. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
MCT First Disclosures
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
Xiaofan Li; Sihong Zhou; Cristina L. Abrahams; Stellanie Krimm; Jennifer Smith; Krishna Bajjuri; Heather T. Stephenson; Robert Henningsen; Jeffrey Hanson; Tyler H. Heibeck; Daniel Calarese; Cuong Tran; Gang Yin; Ryan L. Stafford; Alice Y. Yam; Toni Kline; Venita I. De Almeida; Aaron K. Sato; Mark Lupher, Jr; Kristin Bedard; Trevor J. Hallam
Review
Small Molecule Therapeutics
Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Jeff Hsu; Colin Chong; Jeffrey Serrill; Levina Goon; Joan Balayan; Eric N. Johnson; Grachelle Lorenzana; Sharon Wu; Kevin G. Leong; Theodore J. Yun; Yong Wang; Faming Jiang; Lynne Bannen; Peter Lamb; Wei Xu; Peiwen Yu
Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
Sathyen A. Prabhu; Omar Moussa; Christophe Gonçalves; Judith H. LaPierre; Hsiang Chou; Fan Huang; Vincent R. Richard; Pault Y. M. Ferruzo; Elizabeth M. Guettler; Isabel Soria-Bretones; Laura Kirby; Natascha Gagnon; Jie Su; Jennifer Silvester; Sai Sakktee Krisna; April A. N. Rose; Karen E. Sheppard; David W. Cescon; Frédérick A. Mallette; Rene P. Zahedi; Christoph H. Borchers; Sonia V. del Rincon; Wilson H. Miller, Jr
Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
Antoine Simoneau; Justin L. Engel; Madhavi Bandi; Katherine Lazarides; Shangtao Liu; Samuel R. Meier; Ashley H. Choi; Hongxiang Zhang; Binzhang Shen; Lauren Martires; Deepali Gotur; Truc V. Pham; Fang Li; Lina Gu; Shanzhong Gong; Minjie Zhang; Erik Wilker; Xuewen Pan; Douglas A. Whittington; Scott Throner; John P. Maxwell; Yingnan Chen; Yi Yu; Alan Huang; Jannik N. Andersen; Tianshu Feng
Large Molecule Therapeutics
Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody–Drug Conjugate Efficacy and Toxicity
Arnaud C. Tiberghien; Balakumar Vijayakrishnan; Arman Esfandiari; Mahammad Ahmed; Raul Pardo; John Bingham; Lauren Adams; Kathleen Santos; Gyoung-Dong Kang; Kathryn M. Pugh; Shameen Afif-Rider; Kapil Vashisht; Kemal Haque; Ravinder Tammali; Edward Rosfjord; Adriana Savoca; John A. Hartley; Philip W. Howard
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
Gary Wildey; Ashley M. Shay; Karen S. McColl; Suzy Yoon; Mohammad A. Shatat; Ahmad Perwez; Kyle B. Spainhower; Adam M. Kresak; MaryBeth Lipka; Michael Yang; Mohadese Behtaj; Pingfu Fu; Asrar Alahmadi; Wadad Mneimneh; Ata Abbas; Afshin Dowlati
Models and Technologies
Correction
Correction: Novel Pyrrolo[3,2-d]Pyrimidine Compounds Target Mitochondrial and Cytosolic One-Carbon Metabolism with Broad-spectrum Antitumor Efficacy
Aamod S. Dekhne; Khushbu Shah; Gregory S. Ducker; Jade M. Katinas; Jennifer Wong-Roushar; Md. Junayed Nayeen; Arpit Doshi; Changwen Ning; Xun Bao; Josephine Frühauf; Jenney Liu; Adrianne Wallace-Povirk; Carrie O'Connor; Sijana H. Dzinic; Kathryn White; Juiwanna Kushner; Seongho Kim; Maik Hüttemann; Lisa Polin; Joshua D. Rabinowitz; Jing Li; Zhanjun Hou; Charles E. Dann, III; Aleem Gangjee; Larry H. Matherly
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds